We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Concert Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 85 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 85 → 0 (-85)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $203M → $0 (-$203M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 85

Holders
–
Holders Change
-85
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
85
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
KCM
Kynam Capital Management
New Jersey
-$25.8M
2
BI
BVF Inc
California
-$21.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$11.2M
4
NCM
Nantahala Capital Management
Connecticut
-$10.1M
5
Millennium Management
Millennium Management
New York
-$8.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
– -$2.92M -500,605 Closed
Geode Capital Management
27
Geode Capital Management
Massachusetts
– -$2.44M -417,858 Closed
Two Sigma Advisers
28
Two Sigma Advisers
New York
– -$2.16M -370,500 Closed
Connor, Clark & Lunn Investment Management (CC&L)
29
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$1.7M -290,595 Closed
JP Morgan Chase
30
JP Morgan Chase
New York
– -$1.6M -274,282 Closed
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
– -$1.4M -240,190 Closed
PVI
32
Pura Vida Investments
New York
– -$1.21M -206,525 Closed
IBT
33
International Biotechnology Trust
United Kingdom
– -$1.17M -200,800 Closed
Citigroup
34
Citigroup
New York
– -$1.13M -194,090 Closed
BCM
35
Bridgeway Capital Management
Texas
– -$865K -148,200 Closed
State Street
36
State Street
Massachusetts
– -$823K -140,898 Closed
Northern Trust
37
Northern Trust
Illinois
– -$753K -128,892 Closed
Two Sigma Investments
38
Two Sigma Investments
New York
– -$704K -120,605 Closed
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
– -$665K -113,848 Closed
CAM
40
ClariVest Asset Management
California
– -$603K -103,300 Closed
Ensign Peak Advisors
41
Ensign Peak Advisors
Utah
– -$516K -88,341 Closed
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
– -$509K -87,212 Closed
CANY
43
Caxton Associates (New York)
New York
– -$491K -83,993 Closed
Walleye Capital
44
Walleye Capital
New York
– -$435K -74,548 Closed
BDF
45
Black Diamond Financial
Maryland
– -$415K -71,000 Closed
KIC
46
Kensington Investment Counsel
California
– -$342K -58,599 Closed
RC
47
RBF Capital
California
– -$287K -49,122 Closed
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
– -$275K -47,137 Closed
CSS
49
Cubist Systematic Strategies
Connecticut
– -$270K -46,167 Closed
BC
50
BIT Capital
Germany
– -$228K -39,000 Closed
1
2
3 4

CNCE Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2023, worth a combined $0 — down 100% from $203M a quarter earlier.

Sellers outnumbered buyers: 85 funds closed out of CNCE and 0 opened new positions — a net loss of 85 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Kynam Capital Management, exiting entirely with an estimated $25.8M sold.

  • 0 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $0 of Concert Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2023 and 85 closed out, a net change of -85 holders.
  • The largest Concert Pharmaceuticals, Inc. seller in Q1 2023 was Kynam Capital Management, an estimated $25.8M sold.

Based on aggregated 13F filings for Q1 2023.